{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-214569","form_type":"8-K","ticker":"CCEL","cik":"0000862692","company_name":"CRYO CELL INTERNATIONAL INC","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.832762+00:00","generated_at":"2026-05-14T21:17:15.893232+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NYSE American accepts Cryo-Cell compliance plan; trading continues through Sep 2027","bullets":["Received notice of non-compliance on Mar 12, 2026 for stockholders' deficit and net losses in two of three fiscal years ending Nov 30, 2025.","Compliance plan accepted May 6, 2026; plan period extends to September 9, 2027 to regain listing standards.","Common stock remains listed and traded on NYSE American during plan period, subject to periodic review.","Failure to regain compliance or make progress by deadline could result in delisting proceedings.","Company reported stockholders' deficit as of Nov 30, 2025 and net losses in FY2023, FY2024, FY2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214569","json":"https://secwatch.observer/filing/0001193125-26-214569.json","markdown":"https://secwatch.observer/filing/0001193125-26-214569.md","text":"https://secwatch.observer/filing/0001193125-26-214569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/ccel-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:17:15.893232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"129e84cf0c2c6e11a34ec716fc439494ebe4b31b","claim":"CRYO CELL INTERNATIONAL INC received a nyse_american extension granted notice regarding other.","evidence_excerpt":"May 6, 2026, Cryo-Cell International, Inc. (the \"Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm","confidence":0.75}],"comparable_filings":[{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 6, 2026, Cryo-Cell International, Inc. (the \"Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm","comparable_excerpt":"May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm"}},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 6, 2026, Cryo-Cell International, Inc. (the \"Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}},{"accession":"0001493152-26-025629","ticker":"CDT","company_name":"CDT Equity Inc.","filed_at":"2026-05-28T20:30:30+00:00","headline":"CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025629","json":"https://secwatch.observer/filing/0001493152-26-025629.json","markdown":"https://secwatch.observer/filing/0001493152-26-025629.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 6, 2026, Cryo-Cell International, Inc. (the \"Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm","comparable_excerpt":"May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing\nQualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with\nNasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report\non Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued\nlisting on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm"}},{"accession":"0001493152-26-025454","ticker":"GWAV","company_name":"Greenwave Technology Solutions, Inc.","filed_at":"2026-05-27T21:25:20+00:00","headline":"Greenwave receives second Nasdaq delinquency notice for late Q1 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025454","json":"https://secwatch.observer/filing/0001493152-26-025454.json","markdown":"https://secwatch.observer/filing/0001493152-26-025454.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589149/000149315226025454/0001493152-26-025454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589149/000149315226025454/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 6, 2026, Cryo-Cell International, Inc. (the \"Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm","comparable_excerpt":"May 21, 2026, the Company received an additional delinquency notification letter (the “Notice”) from Nasdaq due to the Company’s\nfailure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1589149/000149315226025454/0001493152-26-025454-index.htm"}},{"accession":"0001213900-26-061545","ticker":"CHAR","company_name":"Charlton Aria Acquisition Corp","filed_at":"2026-05-27T20:41:44+00:00","headline":"Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061545","json":"https://secwatch.observer/filing/0001213900-26-061545.json","markdown":"https://secwatch.observer/filing/0001213900-26-061545.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/0001213900-26-061545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/ea0292193-8k_charlton.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 6, 2026, Cryo-Cell International, Inc. (the \"Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm","comparable_excerpt":"May 22, 2026, Charlton\nAria Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/0001213900-26-061545-index.htm"}},{"accession":"0001213900-26-061511","ticker":"BRLS","company_name":"Borealis Foods Inc.","filed_at":"2026-05-27T20:15:20+00:00","headline":"Borealis Foods receives Nasdaq deficiency notice for delayed Q1 2026 10-Q; supplements prior 2025 10-K notice","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061511","json":"https://secwatch.observer/filing/0001213900-26-061511.json","markdown":"https://secwatch.observer/filing/0001213900-26-061511.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026061511/0001213900-26-061511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026061511/ea0292244-8k_borealis.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 6, 2026, Cryo-Cell International, Inc. (the \"Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm","comparable_excerpt":"May 21, 2026, a notice\n(the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, because the\nCompany has not yet filed the Q12026 Form 10-Q, the Company no longer complies with Nasdaq Lis","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026061511/0001213900-26-061511-index.htm"}},{"accession":"0001829126-26-005698","ticker":"FSHP","company_name":"Flag Ship Acquisition Corp","filed_at":"2026-05-27T13:10:43+00:00","headline":"Flag Ship Acquisition receives second Nasdaq deficiency notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-005698","json":"https://secwatch.observer/filing/0001829126-26-005698.json","markdown":"https://secwatch.observer/filing/0001829126-26-005698.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850059/000182912626005698/0001829126-26-005698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850059/000182912626005698/flagshipacq_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 6, 2026, Cryo-Cell International, Inc. (the \"Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm","comparable_excerpt":"May 21, 2026, Flag Ship Acquisition Corporation\n(the “Company”) received an additional deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) as a res","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850059/000182912626005698/0001829126-26-005698-index.htm"}},{"accession":"0001836875-26-000036","ticker":"NVVE","company_name":"Nuvve Holding Corp.","filed_at":"2026-05-22T22:35:13+00:00","headline":"Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001836875-26-000036","json":"https://secwatch.observer/filing/0001836875-26-000036.json","markdown":"https://secwatch.observer/filing/0001836875-26-000036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/0001836875-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/nvve-20260522.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 6, 2026, Cryo-Cell International, Inc. (the \"Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm","comparable_excerpt":"May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/0001836875-26-000036-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}